CORDIS CROWNs 1997 WITH NEXT-GENERATION CORONARY STENT APPROVAL; FULL-SCALE U.S. LAUNCH BEGINS JAN. 1 THROUGH 100-PERSON DIRECT SALES FORCE
This article was originally published in The Gray Sheet
Johnson & Johnson's Cordis unit began rolling out its Crown second-generation, balloon-expandable coronary stent Jan. 1, seeking to prolong its reign in an increasingly competitive market. Cordis will leverage its 100 person sales force so as to rapidly seed the market with its latest stent offering, parent J&J said Dec. 22 following FDA approval of the device on Dec. 19.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.